ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. - Schaap,F.G.; Rensen,P.C.; Voshol,P.J. (J Biol Chem, 2004)